Dynamic models of viral replication and latency

Current Opinion in HIV and AIDS

Volumn 10, Issue 2, 2015, Pages 90-95

  Mohammadi, Pejman ^a,b,c   Ciuffi, Angela ^a   Beerenwinke, Niko ^b,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

Author keywords

Cure; Dynamic model; HIV; Latency; Transcriptome dynamics

Indexed keywords

CD4+ T LYMPHOCYTE; DYNAMIC MODEL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL ANALYSIS; MECHANISTIC MODEL; MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; STATISTICAL MODEL; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS REPLICATION; BIOLOGICAL MODEL; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1;

TRANSCRIPTOME;

HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; TRANSCRIPTOME; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84925856204     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000136     Document Type: Review

References (38)

1. Durand CM, Blankson JN, Siliciano RF. Developing strategies for HIV-1 eradication. Trends in immunology 2012;33:554-562.
2. Whitney JB, Hill AL, Sanisetty S, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014;512:74-77. This study shows that the viral reservoir is established very early in an animal model.
3. Deng K, Siliciano RF. HIV: early treatment may not be early enough. Nature 2014;512:35-36.
4. Siliciano JD, Siliciano RF. AIDS/HIV rekindled HIV infection. Science 2014;345:1005-1006.
5. Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 2014;111:2307-2312.
6. Cory TJ, Schacker TW, Stevenson M, Fletcher CV. Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS 2013;8:190-195.
7. Pomerantz RJ. Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin Trials 2003;4:137-143.
8. Palmer S, Josefsson L, Coffin JM. HIV reservoirs and the possibility of a cure for HIV infection. J Intern Med 2011;270:550-560.
9. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009;15:893-900.
10. +T cells with stem celllike properties. Nat Med 2014;20:139-142.
11. + T cells from aviremic patients. PLoS Pathog 2013;9:e1003834. This study reveals the multifactorial nature of latently infected cells, being reactivated differently depending on the latency reactivating agent.
12. + T cell model. PLoS Pathog 2014;10:e1004156. The first temporal analysis of the joint viral and cellular transcriptome in a latency model. This study highlights posttranscriptional block and cellular activation status as components of latency.
13. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013;9:e1003174. This study compares the different methods currently used to assess the size of the reservoir.
14. Laird GM, Eisele EE, Rabi SA, et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 2013;9:e1003398.
15. Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013;155:540-551.
16. + T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2014;111:7078-7083. This study shows that SAHA, a latency reactivating agent, fails to induce viral particle production.
17. Ho YC, Laird GM, Siliciano RF. Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals. Proc Natl Acad Sci U S A 2014;111:6860-6861. This study highlights the discrepancy among the defective viral reservoir, the inducible viral reservoir, and the induced viral reservoir.
18. Perelson AS, Ribeiro RM. Modeling the within-host dynamics of HIV infection. BMC Biol 2013;11:96.
19. Selinger C, Katze MG. Mathematical models of viral latency. Curr Opin Virol 2013;3:402-407.
20. Wodarz D. Mathematical models of HIV replication and pathogenesis. Methods Mol Biol 2014;1184:563-581.
21. Petravic J, Ellenberg P, Chan ML, et al. Intracellular dynamics of HIV infection. J Virol 2014;88:1113-1124.
22. Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013;381:2109-2117.
23. Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science 2014;345:169-174.
24. Archin NM, Margolis DM. Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis 2014;27:29-35.
25. Deeks SG. HIV: shock and kill. Nature 2012;487:439-440.
26. Immonen TT, Leitner T. Reduced evolutionary rates in HIV-1 reveal extensive latency periods among replicating lineages. Retrovirology 2014;11:81.
27. Wang S, Rong L. Stochastic population switch may explain the latent reservoir stability and intermittent viral blips in HIV patients on suppressive therapy. J Theor Biol 2014;360:137-148.
28. Hill AL, Rosenbloom DI, Fu F, et al. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A 2014;111:13475-13480. This study sets a quantitative goal for the 'shock and kill' strategies.
29. Petravic J, Martyushev A, Reece JC, et al. Modeling the timing of antilatency drug administration during HIV treatment. J Virol 2014;88:14050-14056.
30. Althaus CL, Joos B, Perelson AS, Gunthard HF. Quantifying the turnover of transcriptional subclasses of HIV-1-infected cells. PLoS Comput Biol 2014;10:e1003871.
31. + T cell line. MBio 2011;2.
32. Chang ST, Thomas MJ, Sova P, et al. Next-generation sequencing of small RNAs from HIV-infected cells identifies phased microrna expression patterns and candidate novel microRNAs differentially expressed upon infection. MBio 2013;4:e00549-e00612.
33. Lefebvre G, Desfarges S, Uyttebroeck F, et al. Analysis of HIV-1 expression level and sense of transcription by high-throughput sequencing of the infected cell. J Virol 2011;85:6205-6211.
34. Mohammadi P, Desfarges S, Bartha I, et al. 24 h in the life of HIV-1 in a T cell line. PLoS Pathog 2013;9:e1003161.
35. + T cells.
36. Britton LM, Sova P, Belisle S, et al. A proteomic glimpse into the initial global epigenetic changes during HIV infection. Proteomics 2014;14:2226-2230.
37. Peng X, Sova P, Green RR, et al. Deep sequencing of HIV-infected cells: insights into nascent transcription and host-directed therapy. J Virol 2014;88:8768-8782.
38. Bullen CK, Laird GM, Durand CM, et al. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014;20:425-429. This study highlights posttranscriptional block and cellular activation status as components of latency.